RP-HPLC is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-11-22. Where a claim depends on a specific study, the study is described rather than over-claimed.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
CO(NH2)2 + H2O → 2 NH3 + CO2 Being a solid highly soluble in water (1200 g/L at 25 °C (77 °F)), urea is much easier and safer to handle and store than the more irritant, caustic and hazardous ammonia, so it is the reactant of choice. Trucks and cars using these catalytic converters need to carry a supply of diesel exhaust fluid, also sold as AdBlue, a solution of urea in water.
MD simulation of the full satellite tobacco mosaic virus (STMV) (2006, Size: 1 million atoms, Simulation time: 50 ns, program: NAMD) This virus is a small, icosahedral plant virus that worsens the symptoms of infection by Tobacco Mosaic Virus (TMV). Molecular dynamics simulations were used to probe the mechanisms of viral assembly. The entire STMV particle consists of 60 identical copies of one protein that make up the viral capsid (coating), and a 1063 nucleotide single stranded RNA genome. One key finding is that the capsid is very unstable when there is no RNA inside. The simulation would take one 2006 desktop computer around 35 years to complete. It was thus done in many processors in parallel with continuous communication between them. Folding simulations of the Villin Headpiece in all-atom detail (2006, Size: 20,000 atoms; Simulation time: 500 μs= 500,000 ns, Program: Folding@home) This simulation was run in 200,000 CPU's of participating personal computers around the world. These computers had the Folding@home program installed, a large-scale distributed computing effort coordinated by Vijay Pande at Stanford University. The kinetic properties of the Villin Headpiece protein were probed by using many independent, short trajectories run by CPU's without continuous real-time communication. One method employed was the Pfold value analysis, which measures the probability of folding before unfolding of a specific starting conformation. Pfold gives information about transition state structures and an ordering of conformations along the folding pathway.
It makes determinations about what objects to prioritize based on what is especially important to Congress or potentially interesting for the public. The 15 million digitized items represent less than 10% of the library's total 160-million-item collection. The library has chosen not to participate in other digital library projects such as Google Books and the Digital Public Library of America, although it has supported the Internet Archive project.
Sources: en.wikipedia.org
From a scientific standpoint, it was a well characterized protein, whose structure had already been elucidated, making it easier to work with, in theory. Additionally, the widely available insulin at the time was pig insulin, and many people presented allergic reactions to this insulin. Human insulin, then, was preferable, for it was believed that people would not have allergic reactions to it. From a business standpoint, there was a large market for insulin; at the time, world sales were greater than $100 million, and growing. Boyer agreed that the insulin hormone should be their first target molecule. After concluding the market research, Swanson prepared Genentech's first business proposal by March 1976. It was with this proposal that Swanson pitched Genentech to Kleiner & Perkins. Perkins later explained that they considered the technical risks to be enormous: "(The risk of failure was) Very high. I figured better than 50–50 we'd lose it... (However) If it worked, the rewards would be obvious.". Boyer's scientific expertise and Swanson's business plan convinced the venture capitalists. While acknowledging the tremendous risk associated with the company, Kleiner and Perkins promised to invest $100,000 in Genentech. This was just a small fraction of Kleiner and Perkins's $8 million venture capital fund.
=== Generic names === Metandienone is the generic name of the drug and its INNTooltip International Nonproprietary Name, while methandienone is its BANTooltip British Approved Name and métandiénone is its DCFTooltip Dénomination Commune Française. It is also referred to as methandrostenolone and as dehydromethyltestosterone. The former synonym should not be confused with methylandrostenolone, which is another name for a different AAS known as metenolone.
=== Height === Kevin Hart's height has been a subject of public curiosity and varying reports, with sources listing him anywhere between 5'2" and 5'5". In an April 2024 interview on 60 Minutes, Hart clarified his actual height, stating: "I'm 5-foot-5, like with a shoe on, like a sneaker. Now, if I put a boot on, I can get to 5'5" and a half." This clarification came after discrepancies in media reports, such as GQ listing him at 5'5" and the Los Angeles Times at 5'4". Hart often incorporates humor about his stature into his stand-up routines.
Calcium carbonate is poorly soluble in pure water (47 mg/L at normal atmospheric CO2 partial pressure as shown below). The equilibrium of its solution is given by the equation (with dissolved calcium carbonate on the right):
Sources: en.wikipedia.org
A&W entered the mainland Chinese market in 1996, the franchisee for the country being Aidewei, and had eight restaurants in Beijing. Later, due to arrears of franchise fees since 2000, Aidewei lost the A&W trademark in 2002. The eight restaurants weren't operating well and were plagued by mismanagement. An outlet in Yansha with 140 seats in a crowded, strategic location turned out to have limited business, while the restaurant in Anzhen had few customers. Following the buyout of the parent chain by Yum! Brands in 2002, it was announced in March 2003 that negotiations with Aidewei had broken down, leading to the franchisee's bankruptcy that same year. The restaurants closed successively from October 2002 to September 2003. The "father of American fast food", as dubbed by the Chinese press, didn't convince the local culture and tastes, especially with the rise of local fast food. There were also concerns about the Chinese branch operating without authorization, refusing to pay franchise fees since September 2000. In 1997 a small A&W restaurant opened in Festivalgate in Osaka, offering standard A&W fare. The restaurant closed in 1999. The first Qatari restaurant opened on December 18, 1997 (Qatar's National Day) with Al-Muftah Group as the franchisee. There were also plans to open a second restaurant in the country, as well as two restaurants in Cairo and six more in the UAE during 1998. The fare was similar to most A&W restaurants, with the addition of local items.
In 2009, the first to obtain FDA approval for topical DMSO usage was PENNSAID, which contains diclofenac in a carrier with 45.5% DMSO Each 1 mL of TDiclo contains 16.05 mg diclofenac sodium. TDiclo solution also contains 45.5% dimethyl sulfoxide (DMSO) vehicle, which can result in enhanced penetration of active drug through the skin. The most common adverse event reported was dry skin at the application site (25.3% of patients), followed by contact dermatitis (13.0%)In interventional radiology, DMSO is used as a solvent for ethylene vinyl alcohol in the Onyx liquid embolic agent, which is used in embolization, the therapeutic occlusion of blood vessels. In cryobiology DMSO has been used as a cryoprotectant and is still an important constituent of cryoprotectant vitrification mixtures used to preserve organs, tissues, and cell suspensions. Without it, up to 90% of frozen cells will become inactive. It is particularly important in the freezing and long-term storage of embryonic stem cells and hematopoietic stem cells, which are often frozen in a mixture of 10% DMSO, a freezing medium, and 30% fetal bovine serum. In the cryogenic freezing of heteroploid cell lines (MDCK, VERO, etc.) a mixture of 10% DMSO with 90% EMEM (70% EMEM + 30% fetal bovine serum + antibiotic mixture) is used. As part of an autologous bone marrow transplant the DMSO is re-infused along with the patient's own hematopoietic stem cells. DMSO is metabolized by disproportionation to dimethyl sulfide and dimethyl sulfone. It is subject to renal and pulmonary excretion.
=== Quinone carriers === Quinones are mobile, lipid-soluble carriers that shuttle electrons (and protons) between large, relatively immobile macromolecular complexes embedded in the membrane. Bacteria use ubiquinone (Coenzyme Q, the same quinone that mitochondria use) and related quinones such as menaquinone (Vitamin K2). Archaea in the genus Sulfolobus use caldariellaquinone. The use of different quinones is due to slight changes in redox potentials caused by changes in structure. The change in redox potentials of these quinones may be suited to changes in the electron acceptors or variations of redox potentials in bacterial complexes.
In addition to structures, nuclear magnetic resonance can yield information on the dynamics of various parts of the protein. This usually involves measuring relaxation times such as T1 and T2 to determine order parameters, correlation times, and chemical exchange rates. NMR relaxation is a consequence of local fluctuating magnetic fields within a molecule. Local fluctuating magnetic fields are generated by molecular motions. In this way, measurements of relaxation times can provide information of motions within a molecule on the atomic level. In NMR studies of protein dynamics, the nitrogen-15 isotope is the preferred nucleus to study because its relaxation times are relatively simple to relate to molecular motions. This, however, requires isotope labeling of the protein. The T1 and T2 relaxation times can be measured using various types of HSQC-based experiments. The types of motions that can be detected are motions that occur on a time-scale ranging from about 10 picoseconds to about 10 nanoseconds. In addition, slower motions, which take place on a time-scale ranging from about 10 microseconds to 100 milliseconds, can also be studied. However, since nitrogen atoms are found mainly in the backbone of a protein, the results mainly reflect the motions of the backbone, which is the most rigid part of a protein molecule. Thus, the results obtained from nitrogen-15 relaxation measurements may not be representative of the whole protein.
=== Copolymers === The copolymer Poly(vinylidene fluoride-co-hexafluoropropylene) or PVDF-HFP is used as a co-polymer in the blades of artificial turf. Addition of organoclay to PVDF-HFP via melt compounding stabilizes the β piezoelectric phase. Copolymers of PVDF are also used in piezoelectric and electrostrictive applications. One of the most commonly used copolymers is P(VDF-trifluoroethylene), usually available in ratios of about 50:50 and 65:35 by mass (equivalent to about 56:44 and 70:30 molar fractions). Another one is P(VDF-tetrafluoroethylene). They improve the piezoelectric response by improving the crystallinity of the material. While the copolymers' unit structures are less polar than that of pure PVDF, the copolymers typically have a much higher crystallinity. This results in a larger piezoelectric response: d33 values for P(VDF-TFE) have been recorded to be as high as −38 p C/N compared to −33 pC/N in pure PVDF.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.